Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
NCT ID: NCT05361486
Last Updated: 2023-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
40 participants
OBSERVATIONAL
2023-08-28
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The implementation package includes the following interventions:
* A revised vivax treatment algorithm that incorporates new Radical Cure tools (G6PD test + Tafenoquine or Primaquine)
* The training of Health Care Providers ( HCPs) in the revised algorithm and the use of the new RC tools
* Patient counselling
* A follow-up visit at Day 3 \[+2 days\] for patients after treatment start
* Accompanying supporting measures: job aids, strengthening of supervision and PV processes
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This implementation research study will be carried out in Peru among 40 Health Care Providers ( HCPs) each treating a minimum of 15 patients with P. vivax malaria. The study will be conducted in Loreto Region (Loreto, Maynas and Ramon Castilla provinces), an area which is endemic for P. vivax.
A total of 30 health facilities will be included: 6 in the first phase and 12 will be added in the second phase. An additional 12 health facilities have been selected as backup in case the malaria case load is low, and this is needed in order to meet the sample size.
All relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for Radical Cure and choosing the appropriate treatment as per their role accordingly.
HCP knowledge and skills regarding semi-quantitative G6PD testing and RC treatment will be assessed through standardized competency assessment (including self-assessments).
Adherence to the revised algorithm will be evaluated as follows. At each HF included in the study, the ideal patient case management cascade will be defined a priori. Individual HCP adherence to each step of the case management will be assessed against this cascade. By indexing each step in the patient care cascade to a specific HCP, the study will be able to consider feasibility at multiple levels, analysing adherence to specific steps of the case management algorithm.
A specific process will be put in place for patient counselling and standard tools such as a counselling checklist will be developed to assist HCPs. In addition, patient materials will be developed which will give explanations on the new Radical Cure tools, emphasize the need to come for a follow-up visit and outline the potential side effects that can be elicited by 8-AQ. Patients will be instructed to come back or call the facilities in case they experience those events.
The study will be carried out in following phases:
1. A formative research and baseline phase ( approx. 3 months) : this phase is meant to collect baseline information from the selected study facilities prior to introduction of the implementation package. This phase will also be important to field-test and validate study tools, such as the training material and documents and data collection tools (e.g. qualitative research questionnaires and interview guides). Finally, during this formative research phase, the supervision processes and tools will be revised.
2. A higher-level facilities phase ( approx. 8 months) : in this phase the implementation package will only be rolled out in selected higher-level facilities.
An interim analysis will be conducted prior to rolling out the implementation package to lower-level facilities. The data cut-off point for this interim analysis will be once 50 patients have been treated with the revised algorithm. During this interim analysis, enrolment in Higher-level HF will continue.
3. An All-level facilities phase ( approx.14 months) : in this phase the implementation package will be rolled out to the lower-level facilities.
Final analysis will be performed at study end and results will be shared with the Peru National Malaria Control Program (NMCP) to make informed decisions on revisions to national malaria treatment policies.
The study aims to achieve the following specific objectives:
1. Assess HCP adherence to a revised case management algorithm for vivax malaria that involves providing RC treatment after semi-quantitative G6PD testing and a follow-up visit. This will be assessed at the provider, patient, and health facility (HF) level.
2. Determine the ability of HCP to safely implement RC treatment after semi-quantitative G6PD testing
3. Evaluate the quality and effectiveness of training and supervision strategies to support the implementation of semi-quantitative G6PD testing before RC treatment
4. Explore barriers and facilitators at the patient, provider, and facility level that mediate effective use of RC treatment with semi-quantitative G6PD testing. 5. Determine the costs associated with introducing semi-quantitative G6PD testing before RC treatment as part of routine care
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Health Care Provider managing vivax patients in study facilities
All HCPs working in the selected facilities who are involved in the management of vivax patients will be approached to participate in the study.
Training on revised algorithm
relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly
Enhancing Pharmacovigilance
Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.
Supervision of malaria services in selected facilities.
Supervisors in target regions will be trained as for the HCPs.
Patients with confirmation of vivax, attending one of the study facilities
All patients aged 6 months onward, who have a confirmed P. vivax infection and who are in a study HF will be approached to participate in the study. This includes pregnant and lactating women, who have a contra-indication to both PQ and TQ, but for whom correct case management will be evaluated as part of the primary endpoints.
G6PD testing
G6PD test after Malaria Vivax diagnosis
Tafenoquine
300 mg (2x150mg tablets) tafenoquine
Primaquine
0.5mg/kg/7 days
Follow Up Visit at Day 3 [+2 days] after treatment start
It will be checked if all patients have a Follow Up Visit at Day 3 \[+2 days\] after treatment start
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Training on revised algorithm
relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly
Enhancing Pharmacovigilance
Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.
Supervision of malaria services in selected facilities.
Supervisors in target regions will be trained as for the HCPs.
G6PD testing
G6PD test after Malaria Vivax diagnosis
Tafenoquine
300 mg (2x150mg tablets) tafenoquine
Primaquine
0.5mg/kg/7 days
Follow Up Visit at Day 3 [+2 days] after treatment start
It will be checked if all patients have a Follow Up Visit at Day 3 \[+2 days\] after treatment start
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients aged 6 months onward, who have a confirmed P. vivax infection and who are treated in a study Health Facilities
* Pregnant and lactating women, who have a contra-indication to both Primaquine and Tafenoquine, but for whom correct case management will be evaluated as part of the primary endpoints.
* Patients providing informed consent and/or informed assent
Exclusion Criteria
6 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Peruana Cayetano Heredia
OTHER
UNITAID
OTHER
ICON plc
INDUSTRY
Medicines for Malaria Venture
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elmer Alejandro Llanos Cuentas, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Universidad Peruana Cayetano Heredia (UPCH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nauta Nucleo- Base
Nauta, Loreto, Peru
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Veronica Soto, MD
Role: primary
Ivan Condori, MS
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Mohrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014 Mar 22;383(9922):1049-58. doi: 10.1016/S0140-6736(13)62568-4. Epub 2013 Dec 19.
Anderle A, Bancone G, Domingo GJ, Gerth-Guyette E, Pal S, Satyagraha AW. Point-of-Care Testing for G6PD Deficiency: Opportunities for Screening. Int J Neonatal Screen. 2018;4(4):34. doi: 10.3390/ijns4040034. Epub 2018 Nov 19.
Chu CS, Bancone G, Kelley M, Advani N, Domingo GJ, Cutiongo-de la Paz EM, van der Merwe N, Cohen J, Gerth-Guyette E. Optimizing G6PD testing for Plasmodium vivax case management and beyond: why sex, counseling, and community engagement matter. Wellcome Open Res. 2020 Aug 25;5:21. doi: 10.12688/wellcomeopenres.15700.2. eCollection 2020.
Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. Am J Trop Med Hyg. 2020 Sep;103(3):1094-1099. doi: 10.4269/ajtmh.20-0186.
Domingo GJ, Advani N, Satyagraha AW, Sibley CH, Rowley E, Kalnoky M, Cohen J, Parker M, Kelley M. Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. Int Health. 2019 Jan 1;11(1):7-14. doi: 10.1093/inthealth/ihy060.
Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, Simpson JA, Soenarto Y, Anstey NM, Price RN. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. PLoS Med. 2017 Aug 29;14(8):e1002379. doi: 10.1371/journal.pmed.1002379. eCollection 2017 Aug.
Edwards SJ, Braunholtz DA, Lilford RJ, Stevens AJ. Ethical issues in the design and conduct of cluster randomised controlled trials. BMJ. 1999 May 22;318(7195):1407-9. doi: 10.1136/bmj.318.7195.1407. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MMV_TQ_21_01
Identifier Type: -
Identifier Source: org_study_id